ClinicalTrials.gg
RecruitingNCT07231705Updated Apr 14, 2026

Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.

An interventional study of Kate Farms Standard 1.2 or Peptide 1.0 in Formula Dependent Children 1 to 2 Years of Age, sponsored by Kate Farms Inc. Recruiting at 1 site in United States. Open to participants aged 12 Months to 17 Months. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Kate Farms Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
12 Months to 17 Months
Sex
All
01

Study summary

The purpose of this prospective study is to evaluate the growth and enteral tolerance of two pea protein-based formulas from Kate Farms in children aged 12 to 17 months who are expected to meet most of their nutritional needs through formula. It is hypothesized that the Pediatric Standard 1.2 and Pediatric Peptide 1.0 formulas will support healthy growth in children between 1 and 2 years of age. The study will assess the impact of these formulas on growth, tolerance, body composition, micronutrient levels, and gut microbiome health in tube-fed children. Formula will be provided for 24 weeks.

Read the detailed description

This is a prospective cohort study. Forty children ages 12-17 months who rely on formula for at least 80% of their nutritional needs (by mouth of tube feeding) are expected to continue this dependence for the next 6 months will be recruited. Children will be recruited from the Feeding Program, GI clinic and Complex Care clinic at Nationwide Children's Hospital in Columbus, Ohio. The study will be introduced to the patient by the provider during a routine clinic visit. Parent consent will be obtained from one of the research investigators during the clinic visit.

The objectives are to study the effect of these formulas on the functions of the body (AND NOT to evaluate its role in any disease state) in the form of growth and nutrition status.

- To sustain/improve to a weight-for-length z-score of between -1 and 0 up through 24 weeks, in children who are predominantly receiving nutrition via formula (either orally or via tube feeding)

Secondary study objectives:

  • To sustain other anthropometric measurements
  • To assess tolerance
  • To assess changes in body composition and gut microbiome
  • To assess changes in key micronutrients.

To sustain the following z scores up through 24 weeks relative to baseline:

  • Weight-for-age
  • Length-for-age
  • Head circumference-for-age
  • Mid upper arm circumference (MUAC)-for-age
  • Weight velocity
  • Length velocity o When ex-preterm infants are recruited, all of these measures will be corrected for gestational age.

Tolerance: Composite measure of tolerance using 3-day diaries:

  • Percentage of feedings that result in spit up/vomiting
  • Average number of stools/day
  • Average stool consistency score using the Brussels Infant and Toddler stool scale
  • Gastrointestinal and Gastroesophageal Reflux (GIGER) Scale for Infant and Toddlers

Body composition: Bioelectrical impedance analysis Gut microbiome: Stool microbiome analysis Micronutrient analysis: Iron and zinc nutriture

02

Conditions studied

  • Formula Dependent Children 1 to 2 Years of Age
03

In context

Lead sponsor

Kate Farms Inc is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 17 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children, male or female, aged 12 through 17 months (for premature infants, we will use corrected age)
  • Children with a weight-for-length z score between ≥ -1.5 at enrolment
  • Children obtaining via formula feeding ≥ 80% of their total energy intake at enrolment and expected to continue to require such formula intake for the next 24 weeks
  • Children from families who are willing and able to comply with the requirements of the protocol
  • Written from the parent or legal guardian
  • Parent/caregiver or legal guardian must be able to read, write, and understand English

Exclusion criteria

Exclusion Criteria:

  • Children with known or suspected complex gastrointestinal anomalies or dysfunction, hepatic or renal dysfunction, or inherited metabolic disorders, suspected or diagnosed conditions associated with malabsorption (e.g. cystic fibrosis) (Note: For hepatic dysfunction, a conjugated >2.0 mg/dL and for renal dysfunction child should not meet any of the Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease (pRIFLE) criteria for renal disease (estimated decreased by 25% by the Schwartz formula or urine output \<0.5 mL/kg per hour over the previous 8 or more hours) or has chronic medical renal disease. We will not obtain labs to exclude children. If children are noted to have liver disease or renal disease in their chart, we will look at their labs to ensure that they do not meet exclusion criteria).
  • Children with tracheostomy and/or inspired oxygen via nasal cannula or children receiving diuretics.
  • Children with known or suspected genetic and/or metabolic inborn errors of metabolism conditions known to interfere with growth or body dysmorphology that can interfere with obtaining standard anthropometric measurements (weight, length, head circumference, and arm circumference)
  • At study entry, children expected to consume on average more than 20% of their energy intake from non-formula sources of nutrition: solids, expressed breast milk and /or parenteral nutrition.
  • Child requiring or expected to have an energy requirement \< 80 kcal/kg per day - Breastfeeding child (who is feeding at the breast > 2 times per day)
  • Child likely to undergo major surgery during the duration of the study
  • Child with a nasogastric tube that is unlikely to get a gastrostomy tube during the duration of the study
  • Principal Investigator's uncertainty about the willingness or ability of the parent/caregiver to comply with the protocol requirements
  • Children whose parent is younger than the legal age of consent
  • Children with known allergy to pea protein or soy or peanuts.
  • Children with a parent or a sibling with a known allergy to pea protein or soy or peanuts.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Formula

    The study intervention will be 2 pea protein-based formulas Kate Farms Pediatric Standard formula 1.2 (KF-PS) and Kate Farms Standard Pediatric Peptide Formula 1.0 (KF-PP).

    Dietary Supplement: Kate Farms Standard 1.2 or Peptide 1.0

Interventions

  • Dietary supplementKate Farms Standard 1.2 or Peptide 1.0

    Kate Farms Standard 1.2 or Peptide 1.0 formulas will be provided by mouth or via tubefeeding. Study children will be fed the formula for a period of up through 24 weeks.

06

What researchers measure

Primary outcomes

  1. Weight-for-length z-score

    To sustain/improve to a weight-for-length z-score of between -1 and 0 up through 24 weeks, in children who are predominantly receiving nutrition via formula (either orally or via tube feeding)

    Time frame: 24 weeks

Secondary outcomes

  1. Weight-for-age

    Z-scores for weight-for-age of between -1 and 0 up through 24 weeks relative to baseline.

    Time frame: 24 weeks

  2. Length-for-age

    Z scores for length-for-age of between -1 and 0 up through 24 weeks relative to baseline.

    Time frame: 24 weeks

  3. Head circumference-for-age

    Z-scores for head circumference-for-age of between -1 and 0 up through 24 weeks relative to baseline.

    Time frame: 24 weeks

  4. Mid upper arm circumference (MUAC)-for-age

    Z-scores for mid upper arm circumference (MUAC)-for-age of between -1 and 0 up through 24 weeks relative to baseline.

    Time frame: 24 weeks

  5. Weight velocity

    Average weight velocity in grams (g)

    Time frame: 24 weeks

  6. Length velocity

    Average length velocity in centimeters (cm)

    Time frame: 24 weeks

  7. Tolerance - Spit up/vomiting

    Percentage of feedings that results in spit up/vomiting based on 3-day food diaries

    Time frame: 24 weeks

  8. Tolerance - Stool

    Average number of stools per day

    Time frame: 24 weeks

  9. Tolerance - Stool consistency

    Average stool consistency using the Brussels Infant and Toddler Stool Scale

    Time frame: 24 weeks

  10. Gastrointestinal (GI) and gastroesophageal (GER) reflux symptoms

    GI and GER symptoms using the Gastrointestinal and Gastroesophageal Reflux (GIGER) Scale for Infants and Toddler

    Time frame: 24 weeks

  11. Body Composition

    Body composition parameters using a bioelectrical impedance analysis

    Time frame: 24 weeks

  12. Gut Microbiome

    Stool microbiome analysis

    Time frame: 24 weeks

  13. Micronutrient analysis

    Iron and zinc nutriture

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Mar 13, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07231705
Lead sponsor
Kate Farms Inc
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Mar 13, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 14, 2026

Study contacts

Taelor Shepherd
Contact
Taelor.Shepherd@nationwidechildrens.org
(614) 722-4239
Praveen Goday, MD
principal investigator · Nationwide Children's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion